BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ihle MA, Huss S, Jeske W, Hartmann W, Merkelbach-Bruse S, Schildhaus HU, Büttner R, Sihto H, Sundby Hall K, Eriksson M, Reichardt P, Joensuu H, Wardelmann E. Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment. PLoS One 2018;13:e0193048. [PMID: 29451912 DOI: 10.1371/journal.pone.0193048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Dalle Fratte C, Guardascione M, De Mattia E, Borsatti E, Boschetto R, Farruggio A, Canzonieri V, Romanato L, Borsatti R, Gagno S, Marangon E, Polano M, Buonadonna A, Toffoli G, Cecchin E. Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib. Front Pharmacol 2020;11:36. [PMID: 32116712 DOI: 10.3389/fphar.2020.00036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Du J, Wang S, Wang R, Wang S, Han Q, Xu H, Yang P, Liu Y. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS). Pathol Oncol Res 2020;26:91-100. [DOI: 10.1007/s12253-019-00770-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
3 Curylova L, Ramos H, Saraiva L, Skoda J. Noncanonical roles of p53 in cancer stemness and their implications in sarcomas. Cancer Lett 2022;525:131-45. [PMID: 34742870 DOI: 10.1016/j.canlet.2021.10.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Bădan MI, Piciu D. Triple Metachronous Malignancies with Thyroid Involvement: A Brief Overview of Five Case Reports over 20 Years of Institutional Experience. Diagnostics (Basel) 2020;10:E168. [PMID: 32245068 DOI: 10.3390/diagnostics10030168] [Reference Citation Analysis]
5 Jilg S, Rassner M, Maier J, Waldeck S, Kehl V, Follo M, Philipp U, Sauter A, Specht K, Mitschke J, Lange T, Bauer S, Jost PJ, Peschel C, Duyster J, Gaiser T, Hohenberger P, Bubnoff N. Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST). Int J Cancer 2019;145:2292-303. [DOI: 10.1002/ijc.32282] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Koga Y, Iwatsuki M, Yamashita K, Kiyozumi Y, Kurashige J, Masuda T, Eto K, Iwagami S, Harada K, Ishimoto T, Baba Y, Yoshida N, Miyanari N, Takamori H, Ajani JA, Baba H. The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors. Gastric Cancer 2019;22:1100-8. [DOI: 10.1007/s10120-019-00950-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Heinrich MC, Patterson J, Beadling C, Wang Y, Debiec-Rychter M, Dewaele B, Corless CL, Duensing A, Raut CP, Rubin B, Ordog T, van de Rijn M, Call J, Mühlenberg T, Fletcher JA, Bauer S. Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs). Clin Sarcoma Res 2019;9:3. [PMID: 30867899 DOI: 10.1186/s13569-019-0112-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]